Analysts supportive of KuraKirin deal despite major selloff in shares
KURA Stock | USD 5.64 0.60 9.62% |
About 57% of Kura Oncology's investor base is looking to short. The analysis of the overall investor sentiment regarding Kura Oncology suggests that many traders are alarmed. The current market sentiment, together with Kura Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Kura Oncology stock news signals to limit their universe of possible portfolio assets.
Kura recently announced deal with Kirin Kyowa for its leukemia drug ziftomenib was viewed favorably by analysts on Thursday, despite shares plunging 38 percent on the news.
Read at seekingalpha.com
![]() |
Kura Oncology Current Investor Sentiment
Comfort Level 43
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Kura Oncology's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Kura Oncology.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Kura Oncology Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kura Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kura Oncology Historical Investor Sentiment
Investor biases related to Kura Oncology's public news can be used to forecast risks associated with an investment in Kura. The trend in average sentiment can be used to explain how an investor holding Kura can time the market purely based on public headlines and social activities around Kura Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Kura Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kura Oncology and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Kura Oncology news discussions. The higher the estimate score, the more favorable the investor's outlook on Kura Oncology.
Kura Oncology Fundamental Analysis
We analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Kura Oncology is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Kura Oncology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kura Oncology stock to make a market-neutral strategy. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics with similar companies.
Peers
Kura Oncology Related Equities
MRUS | Merus BV | 32.55 | ||||
KNSA | Kiniksa Pharmaceuticals | 3.62 | ||||
ERAS | Erasca | 0.83 | ||||
KALV | Kalvista Pharmaceuticals | 0.44 | ||||
INZY | Inozyme Pharma | 0.25 | ||||
DAWN | Day One | 0.32 | ||||
PTGX | Protagonist Therapeutics | 0.54 | ||||
VRDN | Viridian Therapeutics | 0.73 | ||||
CRNX | Crinetics Pharmaceuticals | 1.16 | ||||
DSGN | Design Therapeutics | 1.55 | ||||
GLUE | Monte Rosa | 1.98 | ||||
COGT | Cogent Biosciences | 2.63 | ||||
LRMR | Larimar Therapeutics | 3.11 | ||||
ZNTL | Zentalis Pharmaceuticals | 3.23 | ||||
REPL | Replimune | 4.68 | ||||
SNDX | Syndax Pharmaceuticals | 8.88 |
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |